Literature DB >> 25415570

Pharmaceutical interventions in prescriptions for patients admitted with chronic renal failure.

Paula Arrabal-Durán, M Esther Durán-García, Almudena Ribed-Sánchez, Patricia Hidalgo-Collazos, María Sanjurjo-Sáez.   

Abstract

BACKGROUND: Chronic Renal Failure (CRF) is a disease that requires determined medications dosages to be adjusted.
OBJECTIVES: To assess the characteristics of pharmaceutical interventions concerning the dose adjustment of these drugs in patients with CRF who are admitted into hospital.
METHODS: A 10-month prospective and longitudinal study that calculated the glomerular filtration rate of patients who are brought into the emergency department and had values below 50ml/min/1.73m2. Subsequently, dosage recommendations were provided for the drugs that had not been adapted to the patient’s renal function.
RESULTS: The renal functions of 5311 patients were reviewed. One-hundred and eighty-one (3.4%) had a glomerular filtration rate below 50ml/min/1.73m2 and were receiving drugs that needed to be adjusted. 221 interventions were recorded. Reductions in dosages were the more frequent results (65.6%); 65.6% of these recommendations were accepted by the doctor. The antimicrobial group had the highest number of interventions (57.5%). Internal Medicine (50.2%) was the unit with the most interventions.
CONCLUSION: CRF patients that are admitted into the emergency department are a key objective concerning dosages in chronic renal failure. Pharmaceutical recommendations are highly esteemed by doctors, given their high acceptance. Revising antimicrobial drugs offers more opportunities.

Entities:  

Mesh:

Year:  2014        PMID: 25415570     DOI: 10.3265/Nefrologia.pre2014.Jul.12541

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  1 in total

1.  Promoting clinical pharmacy services through advanced medication review in the emergency department.

Authors:  Ana de Lorenzo-Pinto; Raquel García-Sánchez; Ana Herranz; Iria Miguens; María Sanjurjo-Sáez
Journal:  Eur J Hosp Pharm       Date:  2018-10-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.